The effect of norepinephrine infusion on stroke volume variation(SVV) monitor in different fluid stage before and after mannitol infusion during neurosurgery.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078002

Enrollment

Unknown

Registered

2023-11-27

Start date

2023-12-10

Completion date

Unknown

Last updated

2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral perfusion

Interventions

Maninitol Group:Rapid infusion of mannitol intraoperatively,0.5g/kg within 15 minutes. Before and after administering mannitol or saline, a small dose of norepinephrine is administered through a conc

Control Group:Intraoperative infusion of equal amount of normal saline. Before and after administering mannitol or saline, a small dose of norepinephrine is administered through a concentration increa

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective craniotomy for brain tumors, including meningiomas, gliomas, metastatic tumors, and other patients who require radial artery pressure measurement during surgery, ASA I-III grade 2. Preoperative MRI excluded intracranial hypertension (presence of cerebral pool and absence of midline deviation) 3. Age 18-65 4. Body Mass Index (BMI) 18-25kg/m2 5. Understanding this study and and accepting to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Excluding emergency neurosurgery, minimally invasive neurosurgery, skull repair surgery, ventriculoperitoneal shunt surgery, etc. 2. Excluding patients with intracranial hyper-pressure, consciousness disorder, or pathological neurological signs before surgery. 3. Excluding patients with coronary heart disease, intracranial aneurysm, and intracranial arteriovenous malformation. 4. Excluding patients with fragile brain such as a history cerebral hemorrhage and cerebral infarction. 5. Excluding patients who have used mannitol dehydration before surgery. 6. Excluding patients with narcotic drugs allergy. 7. Excluding patients who refuse to sign the SVV device usage consent form. 8. Excluding patients with severe hepatic and renal disorders.

Design outcomes

Primary

Measure	Time frame
stroke volume variation;systolic blood pressure;central venous pressure;urine output;cadiac output;	—

Secondary

Measure	Time frame
blood glucose and lactate;	—

Countries

China

Contacts

Public ContactLinlin Wang

Department of anesthesiology, Shenzhen People's Hospital

547060119@qq.com+86 136 3167 1660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026